# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win.
The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets.
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster...
Top 10 best performing large-cap stocks last week: Shopify, Palantir, Axon, Fortinet, Trade Desk, Natera, SharkNinja, Zillow, A...
JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and raises the price target from $22 to $24.
Deutsche Bank analyst Steve Powers maintains Kenvue (NYSE:KVUE) with a Buy and raises the price target from $23 to $24.
RBC Capital analyst Nik Modi reiterates Kenvue (NYSE:KVUE) with a Outperform and maintains $24 price target.
UBS analyst Peter Grom maintains Kenvue (NYSE:KVUE) with a Neutral and raises the price target from $20 to $22.